Compare Merck & Co., Inc. (MRK) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs ArcelorMittal SA — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while ArcelorMittal SA trades at $64.11 (market cap $45.70B). The key difference: Merck & Co., Inc. is far larger — about 7.7× ArcelorMittal SA's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and ArcelorMittal SA for 36 Days on average.
| MRK | MT | |
|---|---|---|
Market Cap | $351.28B | $45.70B |
Volume | 7,969,665 | 1,964,621 |
Sector | Health | Basic Materials |
52-Week High | $156.43 | $78.74 |
52-Week Low | $82.49 | $36.91 |
Typical Hold Time | 98 Days | 36 Days |
Enterprise Value | $398.04B | $55.27B |
Dividend Yield | 2.39% | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
ArcelorMittal (MT) trades at $61.30, down 1.64% on the day, with a bearish technical outlook despite recent earnings beats. The company shows mixed fundamentals with declining revenue trends from $79.8B in 2022 to $61.4B in 2025, though net income improved to $3.2B. Recent news highlights operational challenges including a $1B impairment charge from Ukrainian plant closures due to missile strikes, while analyst consensus remains positive with a $74.33 price target.
The stock presents a value opportunity with attractive valuation ratios (P/S 0.75, P/B 0.84) and strong analyst support (52% buy ratings), but faces significant operational risks from geopolitical exposure and declining cash flow trends. Near-term performance depends on European demand recovery and successful execution of growth projects amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
